These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 12049816)

  • 1. The initial evaluation of non-peptidic small-molecule HDM2 inhibitors based on p53-HDM2 complex structure.
    Zhao J; Wang M; Chen J; Luo A; Wang X; Wu M; Yin D; Liu Z
    Cancer Lett; 2002 Sep; 183(1):69-77. PubMed ID: 12049816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study of the cytotoxic effect of a peptidic inhibitor of the p53-hdm2 interaction in tumor cells.
    Chène P; Fuchs J; Carena I; Furet P; García-Echeverría C
    FEBS Lett; 2002 Oct; 529(2-3):293-7. PubMed ID: 12372616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytotoxic effect of a non-peptidic small molecular inhibitor of the p53-HDM2 interaction on tumor cells.
    Li WD; Wang MJ; Ding F; Yin DL; Liu ZH
    World J Gastroenterol; 2005 May; 11(19):2927-31. PubMed ID: 15902730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A small synthetic peptide, which inhibits the p53-hdm2 interaction, stimulates the p53 pathway in tumour cell lines.
    Chène P; Fuchs J; Bohn J; García-Echeverría C; Furet P; Fabbro D
    J Mol Biol; 2000 May; 299(1):245-53. PubMed ID: 10860736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small molecule inhibitors of p53/MDM2 interaction.
    Fotouhi N; Graves B
    Curr Top Med Chem; 2005; 5(2):159-65. PubMed ID: 15853644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benzodiazepinedione inhibitors of the Hdm2:p53 complex suppress human tumor cell proliferation in vitro and sensitize tumors to doxorubicin in vivo.
    Koblish HK; Zhao S; Franks CF; Donatelli RR; Tominovich RM; LaFrance LV; Leonard KA; Gushue JM; Parks DJ; Calvo RR; Milkiewicz KL; Marugán JJ; Raboisson P; Cummings MD; Grasberger BL; Johnson DL; Lu T; Molloy CJ; Maroney AC
    Mol Cancer Ther; 2006 Jan; 5(1):160-9. PubMed ID: 16432175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An alternatively spliced HDM2 product increases p53 activity by inhibiting HDM2.
    Evans SC; Viswanathan M; Grier JD; Narayana M; El-Naggar AK; Lozano G
    Oncogene; 2001 Jul; 20(30):4041-9. PubMed ID: 11494132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular characterization of the hdm2-p53 interaction.
    Böttger A; Böttger V; Garcia-Echeverria C; Chène P; Hochkeppel HK; Sampson W; Ang K; Howard SF; Picksley SM; Lane DP
    J Mol Biol; 1997 Jun; 269(5):744-56. PubMed ID: 9223638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Affinity-based screening of MDM2/MDMX-p53 interaction inhibitors by chemical array: identification of novel peptidic inhibitors.
    Noguchi T; Oishi S; Honda K; Kondoh Y; Saito T; Kubo T; Kaneda M; Ohno H; Osada H; Fujii N
    Bioorg Med Chem Lett; 2013 Jul; 23(13):3802-5. PubMed ID: 23726030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small-molecule inhibitors of the p53-HDM2 interaction for the treatment of cancer.
    Patel S; Player MR
    Expert Opin Investig Drugs; 2008 Dec; 17(12):1865-82. PubMed ID: 19012502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of the p53-MDM2 interaction: targeting a protein-protein interface.
    Chène P
    Mol Cancer Res; 2004 Jan; 2(1):20-8. PubMed ID: 14757842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 1,4-Benzodiazepine-2,5-diones as small molecule antagonists of the HDM2-p53 interaction: discovery and SAR.
    Parks DJ; Lafrance LV; Calvo RR; Milkiewicz KL; Gupta V; Lattanze J; Ramachandren K; Carver TE; Petrella EC; Cummings MD; Maguire D; Grasberger BL; Lu T
    Bioorg Med Chem Lett; 2005 Feb; 15(3):765-70. PubMed ID: 15664854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Requirement for HDM2 activity in the rapid degradation of p53 in neuroblastoma.
    Isaacs JS; Saito S; Neckers LM
    J Biol Chem; 2001 May; 276(21):18497-506. PubMed ID: 11279110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p53-independent activation of the hdm2-P2 promoter through multiple transcription factor response elements results in elevated hdm2 expression in estrogen receptor alpha-positive breast cancer cells.
    Phelps M; Darley M; Primrose JN; Blaydes JP
    Cancer Res; 2003 May; 63(10):2616-23. PubMed ID: 12750288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DIMP53-1: a novel small-molecule dual inhibitor of p53-MDM2/X interactions with multifunctional p53-dependent anticancer properties.
    Soares J; Espadinha M; Raimundo L; Ramos H; Gomes AS; Gomes S; Loureiro JB; Inga A; Reis F; Gomes C; Santos MMM; Saraiva L
    Mol Oncol; 2017 Jun; 11(6):612-627. PubMed ID: 28296148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medicinal Chemistry Strategies to Disrupt the p53-MDM2/MDMX Interaction.
    Lemos A; Leão M; Soares J; Palmeira A; Pinto M; Saraiva L; Sousa ME
    Med Res Rev; 2016 Sep; 36(5):789-844. PubMed ID: 27302609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differentiation of Hdm2-mediated p53 ubiquitination and Hdm2 autoubiquitination activity by small molecular weight inhibitors.
    Lai Z; Yang T; Kim YB; Sielecki TM; Diamond MA; Strack P; Rolfe M; Caligiuri M; Benfield PA; Auger KR; Copeland RA
    Proc Natl Acad Sci U S A; 2002 Nov; 99(23):14734-9. PubMed ID: 12407176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A tryptophanol-derived oxazolopiperidone lactam is cytotoxic against tumors via inhibition of p53 interaction with murine double minute proteins.
    Soares J; Raimundo L; Pereira NA; dos Santos DJ; Pérez M; Queiroz G; Leão M; Santos MM; Saraiva L
    Pharmacol Res; 2015; 95-96():42-52. PubMed ID: 25814188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of the p53-hdm2 interaction with low molecular weight compounds.
    Chène P
    Cell Cycle; 2004 Apr; 3(4):460-1. PubMed ID: 14976429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery, synthesis, and biological evaluation of orally active pyrrolidone derivatives as novel inhibitors of p53-MDM2 protein-protein interaction.
    Zhuang C; Miao Z; Zhu L; Dong G; Guo Z; Wang S; Zhang Y; Wu Y; Yao J; Sheng C; Zhang W
    J Med Chem; 2012 Nov; 55(22):9630-42. PubMed ID: 23046248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.